文章：

慢性淋巴细胞白血病：新型药物时代的预后因素

Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs

原文发布日期：31 July 2024

DOI: 10.3390/cancers16152732

类型: Article

开放获取: 是

英文摘要：

Novel drugs have profoundly changed the outcomes in chronic lymphocytic leukemia (CLL) patients, and the traditional prognostic factors that were identified in the era of chemoimmunotherapy need to be validated in the context of these new targeted therapies. Currently, the most important prognostic genetic biomarkers are the immunoglobulin heavy chain variable (IGHV) mutational status, genetic aberrations including del(17p)/TP53abnormalities, and the complex karyotype. In this review, we discuss the prognostic role of these genomic markers in relation to novel treatments. Moreover, we present and discuss new scoring systems that were elaborated and validated in the era of new drugs. In routine clinical practice, the application of an extensive genomic work-up with validated prognostic markers could improve the identification of “very high-risk” CLL patients who could benefit from novel, more effective targeted treatments.

摘要翻译： 

新型药物已深刻改变了慢性淋巴细胞白血病（CLL）患者的预后，传统化疗免疫治疗时代确立的预后因素需在这些新型靶向治疗背景下重新验证。目前最重要的预后遗传生物标志物包括免疫球蛋白重链可变区（IGHV）突变状态、del(17p)/TP53异常等遗传学畸变以及复杂核型。本文综述了这些基因组标志物与新型治疗方案相关的预后价值，并系统阐述和讨论了新药时代构建并验证的新型评分体系。在常规临床实践中，应用经过验证的预后标志物开展全面基因组检测，有助于更精准识别可能从新型高效靶向治疗中获益的“极高危”CLL患者。

原文链接：

Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs